leisure time -WSS

leisure time

author：comprehensive 2025-09-06 04:15:03 - browse：9754

Terry Horgan pictured at home -- coverage from STAT — Terry Horgan in his family's Montour Falls, N.Y., home, in an undated photo. Kate Collins/The Journal via AP

Last October, a 27-year-old man with Duchenne muscular dystrophy died after receiving a CRISPR-based treatment custom built to treat his particular genetic mutation.

Results of a detailed investigation released on Wednesday suggest that the patient, Terry Horgan, likely died of a previously undocumented adverse effect of the virus used to deliver the CRISPR machinery to his cells.

These viruses, known as adeno-associated viruses, or AAVs, are used in several approved drugs and hundreds of clinical trials to deliver genes into patients, because they are generally benign. But at high doses they can cause side effects and, occasionally, deaths through one of several mechanisms, such as directly injuring the liver or triggering a type of immune response known as complement activation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Prior authorization reform is both possible and imperative

explore

WSS

FDA sets aggressive timeline for overhauling inspection procedures

Google and Epic fight stronger regulation of AI in health care

The inclusion problem at the heart of rehabilitation research

Startup Neumora takes a novel depression drug to Phase 3

Sanders adds drug shortage policies to pandemic preparedness bill

In early work, researchers turn to CRISPR to treat Alzheimer's

hotspot

leisure time

knowledge

New air purifier tech could be key to improving indoor air quality

HPV vaccine, cervical cancer study delivers historic results

Drug repurposing or repositioning? The language matters

Biden tests positive for Covid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sanders adds drug shortage policies to pandemic preparedness bill

ChatGPT in medicine: STAT answers readers' burning questions

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

New air purifier tech could be key to improving indoor air quality

Why hospitals are withdrawing from US News rankings

leisure time

Head of FDA's diagnostics center, who led through Covid, retires

WHO calls for emergency meeting on new China virus, as cases spread

Maisha Meds is a PBM, but don't call it that

Flu vaccine reformulation won't be easy, manufacturers warn

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

focus

explore

explore

hotspot